Aspirin for primary cardiovascular prevention: Why the wonder drug should not be precipitously dismissed

Alberto Aimo, Raffaele De Caterina

Full article

A PDF of the full version of the article can be accessed free of charge through the website of Polish Archives of Internal Medicine.


Primary cardiovascular prevention is the combined set of actions aimed at reducing the likelihood of symptomatic atherosclerotic disease or major adverse cardiovascular events (MACEs) in currently asymptomatic individuals.

Older studies on aspirin for primary prevention were positive or neutral as to the primary ischemic endpoint (often represented by MACE), but the reduction in nonfatal ischemic events seemed largely counterbalanced by an increase in bleeding events. The 3 latest large randomized controlled trials on aspirin in primary prevention, all published in 2018, reached basically similar conclusions, leading to an intense debate on whether aspirin therapy is warranted in asymptomatic patients and whether there are subgroups that may benefit.

In the present review, we provide an overview of the available evidence on aspirin for primary cardiovascular prevention, focusing on the results of meta-analyses and on strengths and pitfalls of meta-analytic assessments. Based on a meta-regression of the benefits and harm of aspirin therapy in primary prevention as a function of the 10-year risk of MACE, which is an alternative type of pooled analysis of available evidence, we propose a treatment algorithm acknowledging differences among patients and emphasizing the need for an individualized assessment of benefits and risks. Following general preventive measures (physical exercise, smoking cessation, treatment of hypertension and hypercholesterolemia, etc), a tailored approach to aspirin prescription is warranted. When patients are younger than 70 years of age, clinicians should assess the 10-year cardiovascular risk: when such risk is high and bleeding risk is low, aspirin treatment should still be considered, also taking patients’ preferences into account.

See also
  • Reinvigorating the clinical examination for the 21st century In the modern American hospital, clinicians spend as little as 12% of their time in direct contact with patients and their families. This has led to a decline in clinical examination skills and contributes to diagnostic error. In 2017, the Society of Bedside Medicine was formed to encourage innovation, education, and research on the role of the clinical encounter in 21st century medicine.
  • Risk mitigation for travelers: Managing endemic and emerging threats International travel has become an increasingly complex issue as a risk factor for infectious diseases. This review examines important considerations when evaluating travelers, with a special focus on the risk of emerging infectious diseases, by placing clinical syndromes in a travel context.
  • Thyroid emergencies This review discusses the clinical presentation, diagnosis, and management of patients presenting with myxedema coma or thyroid storm. If not promptly and appropriately diagnosed and treated, both conditions are associated with poor outcomes and high mortality rates.
  • Should we use ASA in primary prevention? Dr Gordon Guyatt, distinguished professor in the department of Health Research Methods, Evidence, and Impact at McMaster University and one of the founders of EBM, discusses reasons behind using aspirin in primary prevention in light of recent studies.

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.